Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds

Kenneth J. Smith, Bruce Y. Lee, Mary Patricia Nowalk, Mahlon Raymund, Richard K. Zimmerman

Research output: Contribution to journalArticlepeer-review


Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness.

Original languageEnglish (US)
Pages (from-to)7620-7625
Number of pages6
Issue number48
StatePublished - Nov 10 2010
Externally publishedYes


  • Cost-effectiveness
  • Influenza vaccine
  • Pneumococcal polysaccharide vaccine
  • Secondary pneumococcal pneumonia

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds'. Together they form a unique fingerprint.

Cite this